Earlier this year, the administration’s proposal to sharply cut National Institutes of Health funding prompted swift bipartisan opposition. Critics argue that undermining medical research—particularly in fields like Alzheimer’s and obesity—puts urgently needed treatments at risk and worsens the potential impact of MFN pricing on drug innovation.

In a significant setback for President-elect Donald Trump, the House of Representatives rejected his plan to fund government operations and suspend the debt ceiling, heightening the risk of a government shutdown before the midnight deadline.